AI-assisted care plan for cancer patients who also have other illnesses
Tests an AI decision-support system for adults with cancer and other conditions.
Plain-language title generated from the registry record
Registry title: AI-Assisted Comprehensive Management for Cancer Patients With Comorbidities (GCOG-CG001)
Key facts
- Where
- Xinxiang, ChinaSee the site
Where in China
- The First Affiliated Hospital of Xinxiang Medical UniversityXinxiang, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The First Affiliated Hospital of Xinxiang Medical College
- Trial code
- NCT07136727
- Record updated
- 22 August 2025
- Original description
Combined with the digital whole process management data pool, a multi-modal data fusion framework is developed, and an AI model is established to realize risk stratification and personalized treatment Recommendation and dynamic prognosis prediction; validation of whole-process management based on multimodal digital fusion AI-aided decision support system through prospective non-randomized controlled interventional study The effect on survival, complication control and utilization of medical resources in patients with comorbid malignant tumors.Read full original descriptionShow less
The Impact of Multimodal Digital Fusion AI-Assisted Decision Support System-Based Comprehensive Management on Clinical Outcomes in County-Level Patients With Comorbid Cancer:A Prospective Non-randomized Controlled Interventional Study.
Combined with the digital whole process management data pool, a multi-modal data fusion framework is developed, and an AI model is established to realize risk stratification and personalized treatment Recommendation and dynamic prognosis prediction; validation of whole-process management based on multimodal digital fusion AI-aided decision support system through prospective non-randomized controlled interventional study The effect on survival, complication control and utilization of medical resources in patients with comorbid malignant tumors.
Inclusion: Patients with a definite diagnosis of malignancy by histopathology and/or cytology; Age ≥18 years; There is no gender limit; Plan to receive antineoplastic therapy within 2 weeks or are receiving standard antineoplastic care (surgery, radiation, chemotherapy, or targeted therapy) ; Conscious and able to answer questions and use electronic devices autonomously; Patients were able to understand the study and voluntarily sign an informed consent form.
Exclusion: With severe heart disease, acute respiratory failure, liver kidney failure and other critical illness; Having severe mental or cognitive impairments that prevent them from understanding the content of the study or implementing the programme; Women during pregnancy or lactation；; Have participated in other interventional studies in the past 1 month or are currently participating; Patients with ECOG ≥ 3 that do not respond to treatment; Patients with an expected survival of < 3 months that do not respond to treatment; Cases deemed unsuitable for enrollment by the investigator.